BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations

Hitomi Mori, Makoto Kubo, Masaya Kai, Vittoria Vanessa Velasquez, Kanako Kurata, Mai Yamada, Masayuki Okido, Syoji Kuroki, Yoshinao Oda, Masafumi Nakamura

Research output: Contribution to journalArticle

Abstract

We assessed BRCAness as a characteristic of BRCA-mutated breast cancer. We investigated 124 breast cancer patients with a high risk of BRCA mutations, who had early-onset or triple-negative breast cancer. No correlation was found between BRCAness and family history. However, those with a BRCAness tumor and a positive family history had a significantly worse prognosis, which could be of use in predicting the prognosis. Background: The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as “BRCAness” using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (FH) of cancer, in breast cancer patients with a high risk of BRCA mutations. Patients and Methods: The present study included 124 patients, including 55 with early-onset and 77 with triple-negative breast cancer, who had undergone resection at Kyushu University Hospital from 2005 to 2014. Early-onset breast cancer is defined as an onset in patients aged ≤ 40 years. BRCAness was performed using multiple ligation-dependent probe amplification. The patients’ FH of cancer was surveyed from first- to third-degree relatives. Results: Of the 124 patients, the multiple ligation-dependent probe amplification assay results indicated that 59 tumors (47.6%) had BRCAness and 27 patients (21.8%) had a positive FH for cancer. The patients with BRCAness experienced significantly shorter recurrence-free survival (RFS) and overall survival (OS) compared with those without. Patients with FH had shorter RFS and OS compared to those without BRCAness. The patients were divided into those with and without BRCAness and those with and without a positive FH. The BRCAness with FH subgroup experienced significantly shorter RFS and OS. Multivariate analysis revealed that BRCAness and a positive FH were independent negative prognostic factors. Conclusion: Our findings suggest that BRCAness tumors with a positive FH of cancer were associated with a poor prognosis in the BRCA-mutation high-risk group. We propose that BRCAness and a positive FH will serve to predict patients’ prognosis.

Original languageEnglish
Pages (from-to)e1217-e1227
JournalClinical Breast Cancer
Volume18
Issue number5
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Breast Neoplasms
Mutation
Neoplasms
Survival
Triple Negative Breast Neoplasms
Recurrence
Ligation
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations. / Mori, Hitomi; Kubo, Makoto; Kai, Masaya; Velasquez, Vittoria Vanessa; Kurata, Kanako; Yamada, Mai; Okido, Masayuki; Kuroki, Syoji; Oda, Yoshinao; Nakamura, Masafumi.

In: Clinical Breast Cancer, Vol. 18, No. 5, 10.2018, p. e1217-e1227.

Research output: Contribution to journalArticle

Mori, Hitomi ; Kubo, Makoto ; Kai, Masaya ; Velasquez, Vittoria Vanessa ; Kurata, Kanako ; Yamada, Mai ; Okido, Masayuki ; Kuroki, Syoji ; Oda, Yoshinao ; Nakamura, Masafumi. / BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations. In: Clinical Breast Cancer. 2018 ; Vol. 18, No. 5. pp. e1217-e1227.
@article{25472e131cbe4ecaa12fa1fe6a9b3ad8,
title = "BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations",
abstract = "We assessed BRCAness as a characteristic of BRCA-mutated breast cancer. We investigated 124 breast cancer patients with a high risk of BRCA mutations, who had early-onset or triple-negative breast cancer. No correlation was found between BRCAness and family history. However, those with a BRCAness tumor and a positive family history had a significantly worse prognosis, which could be of use in predicting the prognosis. Background: The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as “BRCAness” using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (FH) of cancer, in breast cancer patients with a high risk of BRCA mutations. Patients and Methods: The present study included 124 patients, including 55 with early-onset and 77 with triple-negative breast cancer, who had undergone resection at Kyushu University Hospital from 2005 to 2014. Early-onset breast cancer is defined as an onset in patients aged ≤ 40 years. BRCAness was performed using multiple ligation-dependent probe amplification. The patients’ FH of cancer was surveyed from first- to third-degree relatives. Results: Of the 124 patients, the multiple ligation-dependent probe amplification assay results indicated that 59 tumors (47.6{\%}) had BRCAness and 27 patients (21.8{\%}) had a positive FH for cancer. The patients with BRCAness experienced significantly shorter recurrence-free survival (RFS) and overall survival (OS) compared with those without. Patients with FH had shorter RFS and OS compared to those without BRCAness. The patients were divided into those with and without BRCAness and those with and without a positive FH. The BRCAness with FH subgroup experienced significantly shorter RFS and OS. Multivariate analysis revealed that BRCAness and a positive FH were independent negative prognostic factors. Conclusion: Our findings suggest that BRCAness tumors with a positive FH of cancer were associated with a poor prognosis in the BRCA-mutation high-risk group. We propose that BRCAness and a positive FH will serve to predict patients’ prognosis.",
author = "Hitomi Mori and Makoto Kubo and Masaya Kai and Velasquez, {Vittoria Vanessa} and Kanako Kurata and Mai Yamada and Masayuki Okido and Syoji Kuroki and Yoshinao Oda and Masafumi Nakamura",
year = "2018",
month = "10",
doi = "10.1016/j.clbc.2018.05.008",
language = "English",
volume = "18",
pages = "e1217--e1227",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations

AU - Mori, Hitomi

AU - Kubo, Makoto

AU - Kai, Masaya

AU - Velasquez, Vittoria Vanessa

AU - Kurata, Kanako

AU - Yamada, Mai

AU - Okido, Masayuki

AU - Kuroki, Syoji

AU - Oda, Yoshinao

AU - Nakamura, Masafumi

PY - 2018/10

Y1 - 2018/10

N2 - We assessed BRCAness as a characteristic of BRCA-mutated breast cancer. We investigated 124 breast cancer patients with a high risk of BRCA mutations, who had early-onset or triple-negative breast cancer. No correlation was found between BRCAness and family history. However, those with a BRCAness tumor and a positive family history had a significantly worse prognosis, which could be of use in predicting the prognosis. Background: The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as “BRCAness” using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (FH) of cancer, in breast cancer patients with a high risk of BRCA mutations. Patients and Methods: The present study included 124 patients, including 55 with early-onset and 77 with triple-negative breast cancer, who had undergone resection at Kyushu University Hospital from 2005 to 2014. Early-onset breast cancer is defined as an onset in patients aged ≤ 40 years. BRCAness was performed using multiple ligation-dependent probe amplification. The patients’ FH of cancer was surveyed from first- to third-degree relatives. Results: Of the 124 patients, the multiple ligation-dependent probe amplification assay results indicated that 59 tumors (47.6%) had BRCAness and 27 patients (21.8%) had a positive FH for cancer. The patients with BRCAness experienced significantly shorter recurrence-free survival (RFS) and overall survival (OS) compared with those without. Patients with FH had shorter RFS and OS compared to those without BRCAness. The patients were divided into those with and without BRCAness and those with and without a positive FH. The BRCAness with FH subgroup experienced significantly shorter RFS and OS. Multivariate analysis revealed that BRCAness and a positive FH were independent negative prognostic factors. Conclusion: Our findings suggest that BRCAness tumors with a positive FH of cancer were associated with a poor prognosis in the BRCA-mutation high-risk group. We propose that BRCAness and a positive FH will serve to predict patients’ prognosis.

AB - We assessed BRCAness as a characteristic of BRCA-mutated breast cancer. We investigated 124 breast cancer patients with a high risk of BRCA mutations, who had early-onset or triple-negative breast cancer. No correlation was found between BRCAness and family history. However, those with a BRCAness tumor and a positive family history had a significantly worse prognosis, which could be of use in predicting the prognosis. Background: The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as “BRCAness” using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (FH) of cancer, in breast cancer patients with a high risk of BRCA mutations. Patients and Methods: The present study included 124 patients, including 55 with early-onset and 77 with triple-negative breast cancer, who had undergone resection at Kyushu University Hospital from 2005 to 2014. Early-onset breast cancer is defined as an onset in patients aged ≤ 40 years. BRCAness was performed using multiple ligation-dependent probe amplification. The patients’ FH of cancer was surveyed from first- to third-degree relatives. Results: Of the 124 patients, the multiple ligation-dependent probe amplification assay results indicated that 59 tumors (47.6%) had BRCAness and 27 patients (21.8%) had a positive FH for cancer. The patients with BRCAness experienced significantly shorter recurrence-free survival (RFS) and overall survival (OS) compared with those without. Patients with FH had shorter RFS and OS compared to those without BRCAness. The patients were divided into those with and without BRCAness and those with and without a positive FH. The BRCAness with FH subgroup experienced significantly shorter RFS and OS. Multivariate analysis revealed that BRCAness and a positive FH were independent negative prognostic factors. Conclusion: Our findings suggest that BRCAness tumors with a positive FH of cancer were associated with a poor prognosis in the BRCA-mutation high-risk group. We propose that BRCAness and a positive FH will serve to predict patients’ prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85048879966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048879966&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.05.008

DO - 10.1016/j.clbc.2018.05.008

M3 - Article

C2 - 29941390

AN - SCOPUS:85048879966

VL - 18

SP - e1217-e1227

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -